drugset / Trial / NCT05299593

24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.

NCT05299593

Phase 4 Unknown 43 enrolled Fondazione G.B. Bietti, IRCCS
NaSingle-groupOpen-labelSupportive care

Summary

This is a phase IV, interventional, multi-center, open clinical Trial. Patients will be administered one eye drop of tafluprost/timolol fixed combination at 20:00 (+/- 1 hour), in the treatment of open angle glaucoma and ocular hypertension. The patients will suspend the treatment with latanoprost.

Timeline

Start
2020-06-04
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafluprost Other / unclassified 0.45 ug Other
Subject Timolol Other / unclassified 0.15 mg Other